

## COVID-19 Vaccine Update November 5,2021

### Update Regarding Third Doses:

The following groups of people are now eligible for third doses **6 months (168 days) or more** after their second dose:

- People who received two doses of AstraZeneca/COVIDSHIELD or one dose of the Janssen vaccine
- Adults 70 years of age and older
- First Nations, Inuit and Metis adults
- Adults who are healthcare workers and any staff members, students or volunteers working in a health care organization, including those not providing direct patient care

Starting **Saturday November 6 at 8 AM** individuals who are eligible for third doses can book appointments through:

- Ontario [COVID-19 vaccination portal](#)
- Calling the Provincial Vaccine Contact Centre: 1-833-943-3900
- Through local public health units that use their own booking systems
- Indigenous-led vaccination clinics
- [Select pharmacies](#)
- [Go-Vaxx](#) bus

People whose **immune systems are suppressed due to medications** are eligible for 3<sup>rd</sup> doses as long as at least 28 days has passed since their second dose. See below for the list of eligible medications. If you are on one of these medications there is no need to have a form completed by your doctor; you may book an appointment and **take a copy of the prescription** for the medication that makes you eligible to the vaccine appointment. If you are on a medication that you believe suppresses your immune system that is not on this list, please check with us.

For additional information, please check the following websites:

[COVID-19 Vaccine Third Dose Recommendations](#)

[How to Get Your Third Dose if You are Eligible](#)

In the meantime, please plan to get your flu shot and stay tuned for further updates.

Leslie Beyers      Karen Fleming      Claire Murphy      Jennifer Wyman

### Table 1: List of Immunosuppressant Medications for Third Doses

\*This list may not be comprehensive; health care providers may identify patients on other medications that are significantly immunosuppressive. Prescriptions/ medication bottles for the below immunosuppressant medications can be presented for third doses as needed. If an individual presents a prescription of a medication that is not listed in Table 1, they should be directed to their health care provider to receive a referral form/ letter for a third dose of the COVID-19 vaccine.

<b>Class</b>	<b>Generic Name(s)</b>	<b>Brand Name(s)</b>
Steroids (>20 mg per day of prednisone or equivalent for at least 2 weeks) <sup>3</sup>	• prednisone	
	• dexamethasone	• Decadron
	• methylprednisolone	• DepoMedrol • SoluMedrol • Medrol

<b>Class</b>	<b>Generic Name(s)</b>	<b>Brand Name(s)</b>
Antimetabolites	• cyclophosphamide	• Procytox
	• leflunomide	• Arava
	• methotrexate	• Trexall • Metoject • Otrexup • Rasuvo • Rheumatrex
	• azathioprine	• Imuran
	• 6- mercaptopurine (6-MP)	• Purinethol
	• mycophenolic acid	• Myfortic
	• mycophenolate mofetil	• Cellcept
Calcineurin inhibitors/mTOR kinase inhibitor	• tacrolimus	• Prograf • Advagraf • Envarsus PA
	• cyclosporine	• Neoral • Gengraf • Sandimmune
	• sirolimus	• Rapamune
JAK (Janus kinase) inhibitors	• baricitinib	• Olumiant
	• tofacitinib	• Xeljanz
	• upadacitinib	• Rinvoq

Anti-TNF (tumor necrosis factor)	• adalimumab	<ul style="list-style-type: none"> <li>• Humira</li> <li>• Amgevita</li> <li>• Hadlima</li> <li>• Hulio</li> <li>• Hyrimoz</li> <li>• Idacio</li> </ul>
	• golimumab	• Simponi
	• certolizumab pegol	• Cimzia
	• etanercept	<ul style="list-style-type: none"> <li>• Enbrel</li> <li>• Brenzys</li> <li>• Erelzi</li> </ul>

Anti-TNF (tumor necrosis factor)	<ul style="list-style-type: none"> <li>• infliximab</li> </ul>	<ul style="list-style-type: none"> <li>• Remicade</li> <li>• Avsola</li> <li>• Inflectra</li> <li>• Remsima</li> <li>• Renflexis</li> </ul>
Anti-Inflammatory	<ul style="list-style-type: none"> <li>• Sulfasalazine</li> </ul>	<ul style="list-style-type: none"> <li>• Salazopyrin</li> <li>• Azulfidine</li> </ul>
	<ul style="list-style-type: none"> <li>• 5-Aminosalicylic Acid (ASA)/mesalamine</li> </ul>	<ul style="list-style-type: none"> <li>• Pentasa</li> </ul>
Anti-CD20	<ul style="list-style-type: none"> <li>• Rituximab</li> </ul>	<ul style="list-style-type: none"> <li>• Rituxan</li> <li>• Ruxience</li> <li>• Riximyo</li> <li>• Truxima</li> <li>• Riabni</li> </ul>
	<ul style="list-style-type: none"> <li>• ocrelizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Ocrevus</li> </ul>
IL-1 RA (interleukin-1 receptor antagonist)	<ul style="list-style-type: none"> <li>• anakinra</li> </ul>	<ul style="list-style-type: none"> <li>• Kineret</li> </ul>
	<ul style="list-style-type: none"> <li>• canakinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Ilaris</li> </ul>
Anti-IL6	<ul style="list-style-type: none"> <li>• tocilizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Actemra</li> </ul>
	<ul style="list-style-type: none"> <li>• sarilumab</li> </ul>	<ul style="list-style-type: none"> <li>• Kevzara</li> </ul>
Anti-IL12/IL23	<ul style="list-style-type: none"> <li>• ustekinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Stelara</li> </ul>
Anti-IL17	<ul style="list-style-type: none"> <li>• secukinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Cosentyx</li> </ul>
	<ul style="list-style-type: none"> <li>• ixekizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Taltz</li> </ul>
Anti-IL17R	<ul style="list-style-type: none"> <li>• brodalumab</li> </ul>	<ul style="list-style-type: none"> <li>• Siliq</li> </ul>
Anti-BLyS	<ul style="list-style-type: none"> <li>• belimumab</li> </ul>	<ul style="list-style-type: none"> <li>• Benlysta</li> </ul>
Anti-IL23	<ul style="list-style-type: none"> <li>• guselkumab</li> </ul>	<ul style="list-style-type: none"> <li>• Tremfya</li> </ul>
	<ul style="list-style-type: none"> <li>• risankizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Skyrizi</li> </ul>

Selective T-cell costimulation blocker	<ul style="list-style-type: none"> <li>• abatacept</li> </ul>	<ul style="list-style-type: none"> <li>• Orencia</li> </ul>
	<ul style="list-style-type: none"> <li>• fingolimod</li> </ul>	<ul style="list-style-type: none"> <li>• Gilenya</li> </ul>

S1PR (sphingosine 1-phosphate receptor) agonist	• siponimod	• Mayzent
	• ozanimod	• Zeposia
Phosphodiesterase inhibitors	• apremilast	• Otezla
Anti-integrin	• vedolizumab	• Entyvio